Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Butanolic clevidipine injection vs nicardipine for hypertensive emergency
CTR20201101Phase 3Completed
- Sponsor
- Nanjing Huawei Pharmaceutical Technology Development
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of clevidipine in hypertensive emergency (2 arms), sponsored by Nanjing Huawei Pharmaceutical Technology Development. Primary endpoint: Proportion of subjects achieving target systolic blood pressure within 30 minutes. Started Jul 2020; status: completed.
02
Drugs
clevidipine
03
Conditions
hypertensive emergency
Beyond the preview
Go deeper on CTR20201101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201101.